Trial Profile
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 31 Jul 2018 New trial record